{"name": "Oncothyreon",
 "permalink": "oncothyreon",
 "crunchbase_url": "http://www.crunchbase.com/company/oncothyreon",
 "homepage_url": "http://www.oncothyreon.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "bd@oncothyreon.com",
 "phone_number": "(206) 801-2100",
 "description": "",
 "created_at": "Tue Sep 07 02:21:12 UTC 2010",
 "updated_at": "Mon Jun 03 03:12:16 UTC 2013",
 "overview": "\u003Cp\u003EOncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. Oncothyreon\u00e2\u20ac\u2122s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company\u00e2\u20ac\u2122s lead product candidate under clinical development is a vaccine it calls Stimuvax. Stimuvax incorporates a 25 amino acid sequence of the cancer antigen MUC1, in a liposomal formulation. Stimuvax is designed to induce an immune response to destroy cancer cells that express MUC1, a protein antigen widely expressed on many common cancers, such as lung cancer, breast cancer and colorectal cancer. Oncothyreon has granted an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       36],
      "assets/images/resized/0010/0796/100796v1-max-150x150.png"],
     [[250,
       60],
      "assets/images/resized/0010/0796/100796v1-max-250x250.png"],
     [[324,
       79],
      "assets/images/resized/0010/0796/100796v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Robert",
      "last_name": "L. Kirkman",
      "permalink": "robert-l-kirkman",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Gary",
      "last_name": "Christianson",
      "permalink": "gary-christianson",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Julie",
      "last_name": "M. Eastland",
      "permalink": "julie-m-eastland",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$64.9M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=510806",
    "source_description": " Oncothyreon Announces Pricing of $14.9 Million Private Placement",
    "raised_amount": 14900000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 9,
    "funded_day": 24,
    "investments":
     [{"company":
        {"name": "Cowen Group",
         "permalink": "cowen-group",
         "image":
          {"available_sizes":
            [[[150,
               65],
              "assets/images/resized/0015/5001/155001v1-max-150x150.jpg"],
             [[173,
               76],
              "assets/images/resized/0015/5001/155001v1-max-250x250.jpg"],
             [[173,
               76],
              "assets/images/resized/0015/5001/155001v1-max-450x450.jpg"]],
           "attribution": null}},
       "financial_org": null,
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Iroquois Capital",
         "permalink": "iroquois-capital",
         "image":
          {"available_sizes":
            [[[150,
               45],
              "assets/images/resized/0025/2096/252096v1-max-150x150.png"],
             [[250,
               75],
              "assets/images/resized/0025/2096/252096v1-max-250x250.png"],
             [[267,
               81],
              "assets/images/resized/0025/2096/252096v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Dafna Capital Management",
         "permalink": "dafna-capital-management",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0010/1343/101343v1-max-150x150.jpg"],
             [[170,
               67],
              "assets/images/resized/0010/1343/101343v1-max-250x250.jpg"],
             [[170,
               67],
              "assets/images/resized/0010/1343/101343v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Straus Partners",
         "permalink": "straus-partners",
         "image":
          {"available_sizes":
            [[[150,
               10],
              "assets/images/resized/0026/0112/260112v1-max-150x150.jpg"],
             [[247,
               17],
              "assets/images/resized/0026/0112/260112v1-max-250x250.jpg"],
             [[247,
               17],
              "assets/images/resized/0026/0112/260112v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Downsview Capital",
         "permalink": "downsview-capital",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Heights Capital Management",
         "permalink": "heights-capital-management",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Hudson Bay Capital Management",
         "permalink": "hudson-bay-capital-management",
         "image":
          {"available_sizes":
            [[[150,
               64],
              "assets/images/resized/0008/0380/80380v1-max-150x150.jpg"],
             [[250,
               107],
              "assets/images/resized/0008/0380/80380v1-max-250x250.jpg"],
             [[450,
               192],
              "assets/images/resized/0008/0380/80380v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ramius Advisors",
         "permalink": "ramius-advisors",
         "image":
          {"available_sizes":
            [[[150,
               56],
              "assets/images/resized/0010/3115/103115v1-max-150x150.png"],
             [[165,
               62],
              "assets/images/resized/0010/3115/103115v1-max-250x250.png"],
             [[165,
               62],
              "assets/images/resized/0010/3115/103115v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ayer Capital Management",
         "permalink": "ayer-capital-management",
         "image":
          {"available_sizes":
            [[[150,
               39],
              "assets/images/resized/0021/3325/213325v1-max-150x150.jpg"],
             [[250,
               65],
              "assets/images/resized/0021/3325/213325v1-max-250x250.jpg"],
             [[268,
               70],
              "assets/images/resized/0021/3325/213325v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Hartz Capital",
         "permalink": "hartz-capital",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Kingsbrook Partners",
         "permalink": "kingsbrook-partners",
         "image": null},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/oncothyreon-raises-40m-cancer-work/2011-04-29?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Oncothyreon raises $40M for cancer work",
    "raised_amount": 40000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 29,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://pevc.dowjones.com/article?an=DJFVW00020130530e95upfov6\u0026from=alert\u0026pid=32\u0026ReturnUrl=http%3a%2f%2fpevc.dowjones.com%3a80%2farticle%3fan%3dDJFVW00020130530e95upfov6%26from%3dalert%26pid%3d32",
    "source_description": "Oncothyreon Raises Nearly $10M in PIPE Deal With BVF Partners ",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 5,
    "funded_day": 30,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "2601 Fourth Avenue",
    "address2": "Suite 500",
    "zip_code": "98121",
    "city": "Seattle",
    "state_code": "WA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2013,
   "pub_month": 5,
   "pub_day": 30,
   "stock_symbol": "NASDAQ:ONTY"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}